<DOC>
	<DOCNO>NCT02006160</DOCNO>
	<brief_summary>Cognitive impairment common multiple sclerosis ( MS ) devastate impact functional activity . There great demand medication enhance cognitive capacity MS patient . To date , evidence improvement cognition follow treatment aminopyridines , study topic include neuropsychological ( NP ) test secondary tertiary outcome , methodologically flaw . Dalfampridine may enhance cognition direct pharmacological mechanism , effect motor outcomes prior study . By combine cognition motor outcome propose study , investigator evaluate patient positive effect show beneficial response motor outcome include physical activity motor outcome mediate and/or moderate cognitive improvement dalfampridine</brief_summary>
	<brief_title>Effects Dalfampridine Cognition Multiple Sclerosis</brief_title>
	<detailed_description>3a . Patient Sample Recruitment Subjects consecutively select Western New York ( NY ) region Baird MS Center Jacobs Neurological Institute locate . Patients interview record review assess inclusion/exclusion . Patients approach clinic contact telephone invite participate clinical trial . The attached flier also use directly advertise study patient . Patients initiate contact researcher interview assess eligibility . Inclusion Criteria . Patients eligible study fulfill inclusion criterion specify 1 . Males/Females ≥ 18 year old &lt; 65 year old capable understand comply protocol , include speak write fluent English least 9th grade education . 2 . Have diagnosis MS , per revise McDonald 's Criteria . 3 . Have receive steroid last thirty ( 30 ) day relapse last ninety ( 90 ) day , whose MS consider stable . 4 . Impression cognitive impairment indicate one following : ( ) positive NP test follow diagnosis MS determine board certify neuropsychologist z score &lt; -1.5 expectation least one cognitive domain , ( b ) informant Multiple Sclerosis Neuropsychological Questionnaire ( MSNQ ) &gt; 28 . 5 . An Expanded Disability Status Scale ( EDSS ) ≤ 6.5 . 6 . Have give write informed consent prior study-related procedure part normal medical care , understand consent may withdraw subject time without prejudice his/her future medical care . 7 . Are capable performing requirement NP test battery include least 20/70 near visual acuity near vision chart , correction allow . 8 . If female , must neither pregnant breast-feeding must either ( ) &gt; 12 month post-menopausal surgically sterilize , ( b ) agree use acceptable method birth control duration study . Abstinence consider acceptable method birth control . Exclusion Criteria . Patients exclude study meet one exclusion criterion specify : 1 . Have cognitive deficit cause concomitant medication usage significant neurological/psychological disease e.g . Alzheimer 's disease , Parkinson 's disease , stroke , transient ischemic attack , Vascular Dementia , Huntington 's disease , traumatic brain injury chronic central nervous system ( CNS ) infection 2 . Have evidence medical cause ( ) cognitive impairment 3 . Evidence major mental illness predate onset MS 4 . Have evidence major depression determine positive Beck Depression Index-Fast Screen ( BDIFS ) clinician interview 5 . Have report uncontrolled labile hypertension , tachycardia , cardiovascular cerebrovascular disease 6 . History seizure disorder . 7 . Optic neuritis within 6 month enrollment . 8 . Trigeminal neuralgia . 9 . Prior exposure aminopyridines . Additional Exclusion Criteria optional speech module . Patients eligible enrollment optional speech module meet one exclusion criterion : 1 . Have language/dialect Standard American English first language . 2 . Make use mechanical hearing aid . 3b . Outcome Measures Cognition Endpoints . Psychometric test incorporate gold standard test validate test battery Benedict et al Rao et al [ 7-9 , 47-49 ] . The test order describe : Table 2 . Cognitive Battery Test Domain Time min California Verbal Learning Test 2 ( CVLT2 ) Learning Trials Auditory/Verbal Memory 15 Brief Visuospatial Memory Test Revised ( BVMTR ) Learning Trials Visual/Spatial Memory 05 Paced Auditory Serial Addition Test ( PASAT ) 3 sec Auditory Processing Speed 05 Symbol Digit Modalities Test ( SDMT ) Visual Processing speed 05 Delis Kaplan Executive Function System ( DKEFS ) Sorting Test Executive Function 12 California Verbal Learning Test 2 ( CVLT2 ) Delayed Recall Auditory/Verbal Memory 05 Brief Visuospatial Memory Test Revised ( BVMTR ) Delayed Recall Visual/Spatial Memory 03 Total Time 50 min</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Patients eligible study fulfill inclusion criterion specify : 1 . Males/Females ≥ 18 year old &lt; 65 year old capable understand comply protocol , include speak write fluent English least 9th grade education . 2 . Have diagnosis MS , per revise McDonald 's Criteria . 3 . Have receive steroid last thirty ( 30 ) day relapse last ninety ( 90 ) day , whose MS consider stable . 4 . Impression cognitive impairment indicate one following : ( ) positive NP test follow diagnosis MS determine board certify neuropsychologist z score &lt; 1.5 expectation least one cognitive domain , ( b ) informant MSNQ &gt; 28 . 5 . An Expanded Disability Status Scale ( EDSS ) ≤ 6.5 . 6 . Have give write informed consent prior studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice his/her future medical care . 7 . Are capable performing requirement NP test battery include least 20/70 near visual acuity near vision chart , correction allow . 8 . If female , must neither pregnant breastfeeding must either ( ) &gt; 12 month postmenopausal surgically sterilize , ( b ) agree use acceptable method birth control duration study . Abstinence consider acceptable method birth control . 1 . Have cognitive deficit cause concomitant medication usage significant neurological/psychological disease e.g . Alzheimer 's disease , Parkinson 's disease , stroke , transient ischemic attack , Vascular Dementia , Huntington 's disease , traumatic brain injury chronic CNS infection 2 . Have evidence medical cause ( ) cognitive impairment 3 . Evidence major mental illness predate onset MS 4 . Have evidence major depression determine positive BDIFS clinician interview 5 . Have report uncontrolled labile hypertension , tachycardia , cardiovascular cerebrovascular disease 6 . History seizure disorder . 7 . Optic neuritis within 6 month enrollment . 8 . Trigeminal neuralgia . 9 . Prior exposure aminopyridines within last six month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>